ReproCell

ReproCell Debt-to-Equity

Debt-to-Equity Ratio of ReproCell (4978.T) as of Oct 19, 2026.

Debt-to-Equity

0.00

YoY

-77.04%

Last updated:

Debt-to-Equity Ratio of ReproCell is 2024 0.00 . Debt-to-Equity Ratio of ReproCell was 2023 0.01 . It decreases by -77.04% lower compared to the previous year.

The ReproCell Debt-to-Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt-to-Equity
Date
Debt-to-Equity
Jan 1, 2017
0.01 JPY
Jan 1, 2018
0.01 JPY
Jan 1, 2019
0.01 JPY
Jan 1, 2020
0.01 JPY
Jan 1, 2021
0.01 JPY
Jan 1, 2022
0.01 JPY
Jan 1, 2023
0.01 JPY
Jan 1, 2024
0.00 JPY
The ReproCell Debt-to-Equity history
YEARDebt-to-EquityYoY
0.00-77.04%
0.01+28.99%
0.01-25.74%
0.01+12.37%
0.01+16.85%
0.01-14.28%
0.01+13.55%
0.01-7.59%
0.01+11.41%
0.01-26.67%
0.02—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ReproCell Stock analysis

What does ReproCell do? ReproCell, Inc. is a company that was founded in 2003 and specializes in the research and manufacture of cell cultures. The company is based in Yokohama, Japan and operates worldwide. Its business model includes providing services and products to support research and development activities in the field of regenerative medicine and cell therapy. The company is divided into three main divisions: the Biorepository Division, which provides human cells and tissues for research purposes; the Cell Manufacturing Division, which develops production processes for cell therapy products; and the Drug Discovery Division, which supports drug development through screening and in vitro testing. ReproCell offers a variety of cell cultures, including stem cells from various sources, as well as related media, reagents, and tools for cultivation and application. In addition, the company offers services in cell therapy production, working closely with customers to provide customized and high-quality therapies. ReproCell also supports drug and compound research through screening and in vitro testing, with various platforms available for the identification and evaluation of new compounds. The company has a history of growth and has become a leading player in the field of cell culture and cell therapy production. In conclusion, ReproCell plays a significant role in regenerative medicine and cell therapy production, offering a wide range of products and services to support research and development in these areas. It is poised to continue its growth and contribute to the development of new therapies in the future. ReproCell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ReproCell stock

On Eulerpool you can find the complete historical development of Debt-to-Equity Ratio ReproCell since 2006 – with annual values, charts, and detailed analysis.

The Debt-to-Equity ratio measures financial leverage by comparing total debt to shareholders' equity. Higher ratios indicate more debt financing relative to equity.

Debt/Equity = Total Debt / Shareholders' Equity

A 'good' varies by industry and company stage. On Eulerpool, you can compare Debt-to-Equity Ratio's ReproCell with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — ReproCell

All Key Metrics — ReproCell